8-K: Spero Therapeutics Announces Leadership Changes Amid SEC Investigation, Provides Clinical Trial Update

• Spero Therapeutics is facing an SEC investigation related to disclosures made in 2022 regarding the commercialization of Tebipenem HBr.
• As a result of the SEC investigation, the company has made interim leadership changes, with Esther Rajavelu appointed as Interim President and CEO, and Frank Thomas as Chairman of the Board.
• The former CEO, Satyavrat Shukla, has taken a paid administrative leave but remains on the board, and the former Chairman, Ankit Mahadevia, remains a board member.
• The company's Phase 3 PIVOT-PO trial for Tebipenem HBr has reached over 60% enrollment and is expected to complete enrollment in the second half of 2025.
• Spero estimates its cash and cash equivalents at approximately $52.9 million as of December 31, 2024.
• The company believes its current cash, along with expected milestone payments and other funding, will be sufficient to fund operations into mid-2026.
• The company has suspended development of SPR720 after a Phase 2a trial did not meet its primary endpoint and showed potential safety issues.
• Spero is also planning to initiate a Phase 2 trial for SPR206, contingent on non-dilutive funding.

Score: 4

Explanation: The document contains both positive and negative elements. The progress of the Tebipenem HBr trial and the cash runway are positive, but the SEC investigation, leadership changes, and the suspension of SPR720 development are significant negatives. The overall sentiment is cautiously negative due to the uncertainty surrounding the SEC investigation.

• The Phase 3 trial for Tebipenem HBr is progressing well, with over 60% enrollment completed and expected completion in the second half of 2025.
• The company has a cash runway into mid-2026, providing financial stability for ongoing operations and clinical trials.
• The company has received a Special Protocol Assessment (SPA) agreement from the FDA for the Tebipenem HBr trial, which could support approval.
• Spero has a global commercial partnership with GSK for Tebipenem HBr, which includes significant milestone payments and royalties.
• The company is actively pursuing non-dilutive funding for the SPR206 program.

• Spero is facing an SEC investigation related to past disclosures, which could lead to penalties and legal costs.
• The company has made interim leadership changes due to the SEC investigation, which could create uncertainty.
• The development of SPR720 has been suspended due to disappointing trial results and safety concerns.
• The company's cash position is preliminary and subject to change after the completion of the annual audit.
• The Phase 2 trial for SPR206 is contingent on securing non-dilutive funding.

• The SEC investigation could result in significant financial penalties, legal costs, and reputational damage.
• The company's preliminary cash balance is subject to change and may differ materially from the final audited results.
• The development of Tebipenem HBr is subject to regulatory approval, which is not guaranteed.
• The company's ability to fund its operations beyond mid-2026 is dependent on future funding and milestone payments.
• The company's stock price could be negatively impacted by the SEC investigation and leadership changes.
• The company is dependent on third parties for manufacturing, development, and commercialization of its product candidates.

The company expects to complete enrollment in the Phase 3 PIVOT-PO trial for Tebipenem HBr in the second half of 2025 and anticipates its cash runway will extend into mid-2026. The company will also determine the next steps for the SPR720 program after further data analysis and plans to initiate a Phase 2 trial for SPR206 contingent on non-dilutive funding.

• The Board believes that the Company, Dr. Mahadevia and Mr. Shukla acted in good faith and consistent with their duties and obligations.
• The Board is highly confident that Esther is well equipped to serve as Interim President and CEO and execute on the Companys strategy to advance our pipeline during this period.
• We are entering an important year of progress for Spero, as we build momentum with our Phase 3 Tebipenem HBr PIVOT-PO trial.
• Our cash runway into mid-2026 enables us to stay focused on our highest priority, the tebipenem clinical program and other ongoing activities.

The development of new antibiotics is crucial due to the increasing threat of antimicrobial resistance. Spero's focus on novel treatments for multi-drug resistant bacterial infections aligns with the industry's need for innovative solutions. The company's partnership with GSK highlights the importance of collaboration in addressing this global health challenge.

• Spero's Tebipenem HBr is positioned as a potential first-in-class oral carbapenem for complicated urinary tract infections, which would be a significant advancement over current IV treatments.
• The company's Phase 3 trial design is consistent with industry standards for regulatory approval, including a Special Protocol Assessment (SPA) agreement with the FDA.
• The company's cash runway into mid-2026 is comparable to other clinical-stage biopharmaceutical companies, but the SEC investigation adds a layer of uncertainty.
• The suspension of the SPR720 program is not uncommon in the industry, as drug development often involves setbacks and re-evaluations of clinical programs.
• The company's focus on non-dilutive funding for SPR206 is a common strategy for companies seeking to advance their pipelines without diluting shareholder value.

• Shareholders may experience volatility in the stock price due to the SEC investigation and leadership changes.
• Employees may experience uncertainty due to the leadership changes and the ongoing investigation.
• Customers and partners may be concerned about the company's stability and future prospects.
• Creditors may be concerned about the company's financial health and ability to repay debts.

• Complete enrollment in the Phase 3 PIVOT-PO trial for Tebipenem HBr in the second half of 2025.
• Analyze data from the SPR720 Phase 2a trial to determine next steps for the program.
• Initiate a Phase 2 trial for SPR206, contingent on non-dilutive funding.
• Respond to the SEC Wells Notice and engage in further dialogue with the SEC staff.
• Complete the annual audit of the company's financial statements for the year ended December 31, 2024.

• The company is under investigation by the SEC regarding certain public disclosures made in 2022.
• The SEC has issued a Wells Notice to the company, its former CEO, and its former CFO, indicating a preliminary determination to recommend a civil enforcement action or administrative proceeding.
• The company, Dr. Mahadevia, and Mr. Shukla are cooperating with the SEC and intend to vigorously defend against the matter.

• 2022-03-31: Start date of the period of public disclosures under SEC investigation.
• 2022-05-03: Date Spero announced it would cease commercialization of tebipenem HBr based on FDA feedback.
• 2023-07: SPR720 Phase 2a proof-of-concept trial concluded enrollment.
• 2023-11: Esther Rajavelu joined Spero as Chief Financial and Business Officer.
• 2023-12: PIVOT-PO trial began enrolling patients.
• 2024-01: PIVOT-PO trial began enrolling patients.
• 2024-07: SPR720 Phase 2a proof-of-concept trial concluded enrollment.
• 2024-12-31: Date of estimated cash and cash equivalents of $52.9 million and 60% enrollment in PIVOT-PO trial.
• 2025-01-07: Date of interim leadership changes approved by the board.
• 2025-01-09: Spero responded to a Wells Notice from the SEC.
• 2025-01-10: Date of the press release and 8-K filing announcing leadership changes and corporate update.